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Cytotoxic T lymphocytes (CTL) recognize viral pep-
tidic antigens presented by major histocompatibility
complex (MHC) class I molecules on the surface of in-
fected cells. The CTL response is critical in clearance
and prevention of HIV infection. Yet, there are no de-
scriptions of physiological peptides derived from the
viral envelope protein. In the few reports on endoge-
nous MHC class I viral peptidic ligands from HIV inter-
nal proteins, definitive positive identification by mass
spectrometry is lacking. The HIV-1 envelope glycopro-
tein gp160 induces a strong specific CTL response re-
stricted by several human and murine MHC class I mol-
ecules, including H-2Dd. Previous analyses showed that
this response can be optimally mimicked with the syn-
thetic decameric peptide 318RGPGRAFVTI327. We aim to
identify the endogenous natural peptides mediating the
response to this epitope. Our data indicate the presence
of, at least, two peptidic species of different length and
sharing the same antigenic core, which are associated
with the Dd presenting molecule in infected cells. One
species is at least, probably, the optimal decapeptide.
The second species, identified by mass spectrometry for
the first time in HIV, is, unexpectedly, a nonamer, which
lacks the correctly positioned N-terminal group to bind to
Dd. And yet, it is present in similar amounts and, notably,
is equally antigenic. Thus, the physiological set of HIV-
derived MHC class I ligands is richer and different than
expected from studies with synthetic peptides. This may
help raise the plasticity and thus the effectiveness of the
immune response against the viral infection. These data
have implications for HIV vaccine development.
The cellular immune response mediated by CD8 cytotoxic T
lymphocytes (CTL)1 plays an important role in controlling
HIV-1 infection (1, 2). There is a temporal correlation between
vigorous CTL responses and initial control of HIV replication
during primary infection (3, 4). Also, there is an important
presence of CTL response in long-term nonprogressors com-
pared with progressors (5, 6). In addition, in SIV-infected ma-
caques the abrogation of the CD8 population induces a high
increase in viral load that in turn causes animal death (7).
Furthermore, homozygosity at any HLA locus is strongly asso-
ciated with rapid progression to disease (8). In addition, some
loci such as HLA-B35 (8) and -B27 (9) are individually associ-
ated with faster and slower development of AIDS, respectively.
The virus escapes this CTL response (10, 11), which confirms
that CD8 T lymphocytes exert an immunological pressure
(12). This evidence indicates a protective role of CTL in pre-
venting and controlling HIV infection. For this reason, charac-
terization of epitopes recognized by CTL represents an impor-
tant contribution in the development of therapeutic agents
such as vaccines against the virus. Identification of the natu-
rally processed epitopes will assure their correct inclusion in
vaccine formulations, and help improve the efficiency of endog-
enous antigen presentation by MHC class I molecules to poten-
tiate the CTL response. Notably, there are no reports of iden-
tification of endogenous peptides derived from any epitope
recognized by CTL in the HIV envelope protein, and very few
descriptions from HIV internal proteins (13–15).
In the BALB/c mouse model, the HIV-1 strain IIIB envelope
glycoprotein gp160 induces a CTL response restricted by the
H-2Dd class I molecule (16). Analysis of overlapping synthetic
peptides covering practically all the gp160 sequence revealed
that the 15mer peptide 315RIQRGPGRAFVTIGK329 (then
named p18) was the major one recognized by CTL (16). After-
ward, additional experiments described the short 318RG-
PGRAFVTI327 synthetic peptide (herein named R10I) as the
most antigenic within this sequence (17–21). This region is
particularly interesting because it contains epitopes for at least
13 different MHC class I molecules from various species (6
murine, 5 human, 1 chimpanzee, and 1 macaque), including
HLA alleles frequent in the human population (HLA-A2, -A3,
-A24, -A11, and -A30) (22). Thus, this viral region, known as
V3, is recognized by CTL from an important fraction of pa-
tients, which is a paradox because it is one of the regions of the
HIV genome that is more variable among virus strains.
However, all experiments have been performed with syn-
thetic peptides. We are interested in the study of the natural
peptides responsible for this Dd-restricted, envelope glycopro-
tein-specific, CTL response. This report shows that the endog-
enous proteolytic processing of gp160 protein for presentation
to CTL generates at least two viral-derived peptidic species
bound to the presenting molecule in infected cells. One of them
may correspond to the optimal synthetic peptide, while a sec-
ond one is an unexpected shorter species. In addition, our
* This work was supported by grants from the European Union,
Ministerio de Educación y Ciencia, Comisión Interministerial de Cien-
cia y Tecnologı́a, Comunidad de Madrid, Instituto de Salud Carlos III,
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results exclude as natural Dd ligand at least one synthetic
peptide that is as antigenic as the natural peptides. These
results underscore the need to study the peptides resulting
from physiological processing, because the natural situation
can be more complex than the optimum detected with
synthetic peptides.
EXPERIMENTAL PROCEDURES
Mice—BALB/c mice (H-2d haplotype) were bred in our colony.
Cell Lines—All cell lines were cultured in IMDM supplemented with
10% fetal calf serum and 5  105 M 2-mercaptoethanol. The P13.1 cell
line is a derivative from mouse mastocytoma P815 cells (H-2d) by
transfection with the lacZ gene encoding -galactosidase (23). For in-
fection, untransfected murine kidney L cells (Ltk cells) and L cells
transfected with Dd were used (24). For stability assays, the TAP-
deficient human lymphoblastoid T2 cells were employed (25).
Synthetic Peptides—Peptides were synthesized in a peptide synthe-
sizer (model 433A; Applied Biosystems, Foster City, CA), and purified,
when needed, by cation-exchange and/or reversed-phase HPLC (RP-
HPLC). They were quantitated by A280 absorbance using peptide R10I
as a standard, and the identity confirmed by matrix-assisted laser
desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry.
All peptide sequences were derived from the sequence 313KIRIQRG-
PGRAFVTIGKIGNMRQAH337, which forms part of the V3-loop anti-
genic area from HIV-1 strain IIIB envelope glycoprotein. They are
named indicating the first amino acid, the length, and the last amino
acid. Thus, R10I refers to the decamer of sequence 318RGPGRAFVTI327.
See Table I for an overview.
Recombinant Vaccinia Viruses (rVV)—rVV-ENV (vSC25) encodes
ENV envelope glycoprotein gp160 from the strain IIIB of HIV-1 (27). Its
DNA sequence was confirmed. rVV-eC-10env encodes the HIV-1 strain
IIIB ENV 318–327 epitope, corresponding to the decamer sequence
R10I, inserted into the carboxyl end of HBe. The sequence at that site
is ...RRSQSRGPGRAFVTIRESQC (28). The negative control rVV-HBe
encodes the carrier protein HBe, the hepatitis B virus secretory core
protein (29). rVV-encoded proteins relevant to this study contain their
respective signal sequences for translocation into the endoplasmic re-
ticulum. All foreign genes cloned into the rVV used in this study are
under the control of the vaccinia early-late promoter 7.5k. rVV-HBe and
rVV-eC-10env are based on vaccinia Copenhagen strain, whereas rVV-
ENV and rVV-Dd (30) present vaccinia Western Reserve (WR)
background.
T Cell Lines and Cytotoxicity Assays—Polyclonal ENV-IIIB-mono-
specific CTL were generated by immunization of mice with 5  107
plaque-forming units (PFU) of rVV-ENV, followed by weekly restimu-
lation of splenocytes with 106 M G9I synthetic peptide and interleukin
2, as described elsewhere (28). They were used as effector cells in
standard 6-h cytotoxicity assays. Identical cytolytic pattern with differ-
ent IIIB ENV 317–327 epitope peptides was found by restimulation
with R10I (data not shown). As targets, L/Dd cells were infected over-
night with rVV as described (31). For peptide titrations, P13.1 targets
and peptides were incubated for 20 min and CTL were then added.
When brefeldin A (BFA) (Sigma-Aldrich) was employed to block transit
of MHC/peptide complexes along the secretory pathway, the percentage
of specific inhibition was calculated as shown in Equation 1,
% Specific inhibition 
[E N]  [Eb  Nb]
[E  N]
 100 (Eq. 1)
where E is lysis rVVENV, N is lysis rVVNEGATIVE CONTROL, Eb is lysis
rVVENV  BFA, and Nb is lysis rVVNEGATIVE CONTROL  BFA.
BFA was used as described (28), except that it was added in a 5-fold
higher concentration during the preincubation time (30 min before
addition of the virus) than throughout infection.
Isolation of Naturally Processed Peptides—L cells (3  109 in 30
roller bottles) were infected with rVV at a multiplicity of infection
(m.o.i.) of 3.5 PFU per cell, and 16 h later naturally processed peptides
were extracted from whole cells with trifluoroacetic acid (29, 32) and
purified by RP-HPLC (33). Control extractions were performed identi-
cally, except that pellets of 109 P13.1 cells received 10 nmol of R10I and
Q11I peptides immediately after addition of trifluoroacetic acid. Pooled
RP-HPLC fractions that tested positive in cytotoxicity assays with
P13.1 target cells and ENV-specific CTL were newly chromatographed
by cation-exchange chromatography in a MonoS PC1.6/5 column (Am-
ersham Biosciences). Elution was accomplished with a NaCl gradient in
7 mM sodium acetate, pH 4, 30% acetonitrile. Fractions from this second
column and dilutions thereof were analyzed in new cytotoxicity assays.
As internal standard, an ENV-unrelated peptide was included in all
HPLC runs. To ensure comparability of different runs, the actual con-
ductivity gradient was always monitored. Contamination of the HPLC
columns was excluded by testing preceding HPLC runs with CTL. For
standardization, serial dilutions of synthetic peptides were tested al-
ways in parallel.
Mass Spectrometry—HPLC fractions containing peptides from the
cellular extracts were dried and dissolved in 5 l of 0.1% formic acid in
methanol:water 1:1 and sequenced by Dr. J. Vázquez (Centro de Biolo-
gı́a Molecular, Madrid, Spain) by quadrupole ion trap nanoelectrospray
MS/MS in an LCQ mass spectrometer (Finnigan ThermoQuest, San
José, CA). The charge and the mass of the ionic species were determined
by high-resolution sampling of the mass/charge rank. Collision energy
and ion-precursor resolution were improved to optimize the fragmen-
tation spectrum.
MALDI-TOF mass spectrometry was performed in a Reflex instru-
ment (Brucker-Franzen Analytik, Bremen, Germany) operating in the
positive ion reflection mode, by Dr. J. P. Albar (Centro Nacional de
Biotecnologı́a, Madrid, Spain). Twenty-five microliters of a given HPLC
fraction were dried, resuspended in 2 l of 0.1% trifluoroacetic acid in
a 2:1 solution of water:acetonitrile, and mixed with 2 l of saturated
-cyanohydroxycinnamic acid matrix in the same solution. One micro-
liter of the mixture was dried and subjected to analysis.
MHC/Peptide Stability Assays—TAP-deficient T2 cells were infected
at 26 °C with rVV-Dd at a m.o.i. of 3, and 14 h later they were washed
and incubated for 2 h at 37 °C in phosphate-buffered saline containing
0,1% bovine serum albumin and 500 M of the different peptides, as
described (32). After washing (time point 0), the cells were further
incubated at 37 °C. Aliquots removed at different time points were
stained with mAb 34-5-8S, which recognizes Dd bound to peptides (34),
followed by flow cytometry (32). Cells incubated without peptide had
peak fluorescence intensities close to background staining with second
Ab alone. Fluorescence index was calculated at each time point as the
ratio of peak channel fluorescence of the sample to that of the control
incubated without peptide.
Intracellular Cytokine Staining (ICS)—Intracellular cytokine stain-
ing assays were performed as described previously (35). Splenocytes
were obtained from BALB/c mice 7 or 33 days after infection with 5 
107 PFU of rVV, stimulated with 105 M peptide for 30 min or for 2 h,
respectively, and stimulated for a further 3 h in the presence of 10
g/ml BFA. The assays were performed in the absence of fetal calf
serum. Following stimulation, cells were incubated with FITC-conju-
gated anti-CD8 (clone 53–6.7) mAb for 30 min at 4 °C, fixed with
Intrastain kit (DakoCytomation, Glostrup, Denmark) reagent A, and
incubated with PE-conjugated anti-IFN- mAb in the presence of In-
trastain kit permeabilizing reagent B for 30 min at 4 °C. All antibodies
were purchased from BD PharMingen (San Diego, CA). Events were
acquired using a FACSCalibur flow cytometer (BD Biosciences, San
Jose, CA), and data were analyzed using CellQuest software (BD
Biosciences).
RESULTS
Presentation of the HIV-1 Envelope Glycoprotein Requires
Endogenous Processing—In BALB/c mice the CTL response
against HIV-1 strain IIIB envelope glycoprotein is restricted by
the Dd class I molecule (16). Glycoprotein-specific CTL recog-
nize 318RGPGRAFVTI327 decamer-pulsed target cells (17, 18),
and other extended nested peptides from the same antigenic
region (18, 20). Infection of L/Dd cells with a rVV that codes for
the full-length glycoprotein, rVV-ENV, induces specific recog-
nition by CTL (Fig. 1A, squares). In addition, the decamer
318RGPGRAFVTI327 (named R10I thereafter) is efficiently pre-
sented both as exogenous synthetic peptide (66% specific lysis
versus 0% without peptide at an E:T ratio of 5:1) and also when
included in the C terminus of the heterologous HBe secretory
protein and expressed endogenously by rVV-eC-10env (Fig.
1A, circles).
In order to confirm that the presentation of the envelope
glycoprotein in L/Dd cells requires endogenous processing, cy-
totoxicity assays were performed in the presence of BFA. This
drug blocks class I export beyond the cis-Golgi compartment
(36), thus preventing the expression of newly endogenously
assembled MHC/peptide complexes at the membrane. Exog-
enously added peptides are not affected by BFA, and thus no
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inhibition was found when WR-infected cells pulsed with R10I
peptide were treated with BFA (data not shown). In contrast,
Fig. 1B shows a significant decrease in the recognition of the
native glycoprotein (73  9.5%) and the chimeric construct
(100  4.2%) when infection with the respective rVV was per-
formed in the presence of BFA. Thus, CTL recognition of this
ENV epitope in association with the Dd molecule requires proc-
essing of endogenously synthesized proteins in infected L/Dd
cells, similarly to other cell lines (28, 37).
The Endogenously Processed Peptides Are Associated with Dd
in the Infected Cell—In order to identify the natural endog-
enously processed peptides of the gp160 protein that are asso-
ciated with the Dd molecule, an acid extraction of the peptides
generated after infection of L/Dd cells with rVV-ENV was per-
formed. The peptides were separated by RP-HPLC (Fig. 2) and
analyzed in cytotoxicity assays. This analysis showed a major
antigenic activity around fraction 16 (Fig. 2, closed symbols).
The CTL did not recognize WR-infected target cells, indicating
the specificity of the antigenic peak.
Whole cells rather than antibody-selected Dd were used for
natural peptide extraction, in order not to exclude potential
precursor peptides. Because of this, it was interesting to test
whether this antigenic activity was detected only when Dd was
present. Therefore, extraction experiments were carried out
using the Dd-negative parental Ltk cells, using similar in-
fected cell equivalents as tested previously with Dd-positive
cells, and CTL of confirmed identical sensitivity. No antigenic
peaks were found in the RP-HPLC runs from infected Ltk
cells (Fig. 2, crosses). These results indicate that peptides gen-
erated by endogenous processing of the envelope glycoprotein
in infected L/Dd cells and detected in Fig. 2 must be bound to
the presenting Dd molecule, and are therefore neither free from
MHC, nor bound also to the endogenous H-2k molecules of L
cells.
Physiological Processing Generates at Least Two Different
Dd-associated Peptidic Species, One of Them Unexpectedly
Monocharged—Even though the gradient used for elution of
the peptides from the RP-HPLC column was rather flat, several
different overlapping synthetic peptides from the antigenic
region encompassing ENV residues 313–337 eluted near frac-
tion 16 (see below). This is probably because all these peptides
have related, low hydrophobicity, as all of them are positively
charged. This impeded further characterization of the endoge-
nous peptides generated. Therefore, in an attempt to resolve
the peptidic species that correspond to the antigenic peak that
was obtained in the RP-HPLC column, the pool of fractions
14–22 containing antigenicity as revealed by the cytotoxicity
assay (Fig. 2) was newly chromatographed by cation-exchange
HPLC. Fig. 3 shows two different antigenic peaks generated as
a result of the endogenous processing of the envelope glycopro-
tein in L/Dd cells. The first antigenic activity (fractions 21–22)
corresponds to monocharged species, while the second peak
(fractions 35–37) groups some bi-charged and some tri-charged
peptides. Synthetic peptides from this antigenic area, up to 15
residues long, were tested to also set the elution positions for
other peptidic species with up to 4 positive charges. Accord-
ingly, further fractions were collected up to number 60 to cover
peptidic species up to 4 charges, but these contained no anti-
genicity (Fig. 3).
The first antigenic activity (fractions 21–22) in the ion ex-
change column coelutes with the only two monocharged syn-
thetic peptides from this area that contain the epitope core:
G10G and G9I (see Table I for a summary of results). Shorter
mono-charged peptides P8I and G7I also co-elute (data not
shown). Since G10G elutes away from the antigenic fractions in
RP-HPLC, we excluded this peptide from further analysis. We
next tested the recognition of the three peptides that coelute
with the antigenic peaks in both HPLC analyses. Fig. 4A shows
that G9I is efficiently recognized by specific CTL, with a similar
titration curve as R10I (see below, Fig. 7). In contrast, P8I was
recognized 1000-fold less than G9I, and G7I was not recognized
at all, as also found by Bergmann et al. (19). G10G, already
excluded as a candidate natural peptide, was essentially not
recognized either (Table I). Because reports in the literature
(18–20) sharply disagree on the antigenicity of G9I, it was
FIG. 2. Natural endogenous peptides generated after process-
ing of ENV in Dd-positive cells. Peptides extracted from L/Dd cells
infected with rVV-ENV at a m.o.i. of 3.5 were separated by RP-HPLC.
Fractions were tested with ENV-specific CTL to analyze the presence of
antigenic peptides. The results obtained with 2.88  108 (●), 1.44  108
(Œ), and 0.72  108 (f) cell equivalents per well of the cytotoxicity assay
are depicted. An identical experiment was carried out with 1.16  108
infected cell equivalents of the Dd-negative Ltk cells (x, L). At right,
the secondary scale indicates the monitored acetonitrile gradient (solid
line) employed for elution.
FIG. 3. Different peptidic species result from endogenous ENV
antigen processing. Antigenic fractions 14–22 from the RP-HPLC
run shown in Fig. 2 were pooled and separated by cation-exchange
chromatography (IE-HPLC). This was followed by a cytotoxicity assay
of the collected fractions. The results obtained with 1.13  108 (●),
0.56  108 (Œ), and 0.28  108 (f) cell equivalents of the peptide
extracts from Dd-positive cells infected with rVV-ENV virus are plotted.
Right, the secondary scale indicates the monitored conductivity of the
NaCl gradient (solid line) employed for elution.
FIG. 1. Endogenous presentation of ENV by the MHC class I
molecule Dd. Panel A, recognition of ENV by CTL. L/Dd cells were
infected overnight with rVV-ENV (f) or with rVV-eC-10env, which
encodes the R10I epitope sequence (●), at a m.o.i. of 10, and were
analyzed with ENV-specific CTL in a cytotoxicity assay. rVV-HBe (Œ)
and WR (x) were employed as negative controls at the same m.o.i. As a
positive control, recognition by CTL of WR-infected cells prepulsed with
105 M R10I synthetic peptide gave lysis values of 65, 71, and 66% at
E:T ratios of 20:1, 10:1, and 5:1, respectively. Panel B, inhibition by
BFA (5 g/ml) of the recognition of the ENV epitope by CTL in rVV-
infected cells. The data are mean values of at least two experiments.
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tested and excluded that our G9I was contaminated with a
more antigenic species, specifically with the bi-charged R10I
peptide, by using both mass spectrometry and CTL testing of
cation-exchange HPLC runs of either G9I or R10I peptides
separately (data not shown).
In addition, MHC/peptide complex stability assays using
TAP-deficient T2 cells infected with rVV-Dd were carried out.
Fig. 4B shows that G9I induces a high number of complexes
with the presenting molecule whereas both P8I and G7I induce
much fewer and markedly less stable complexes. Therefore, the
short P8I and G7I peptides cannot be considered reasonable
candidates for natural peptides and, thus, the first antigenic
activity detected by ion exchange HPLC must be assigned to
the G9I peptide.
This preliminary conclusion was validated by mass spec-
trometry analysis of the cation exchange column antigenic
fraction. Despite the exposure of the cellular extracts to NaCl
during peptide elution (Fig. 3), which interferes with ioniza-
tion, and despite the presence of an R in the peptide sequence,
which disfavors detection of the N-terminal fragments, quadru-
pole/ion trap mass spectrometry showed that fraction 21 un-
equivocally contained G9I peptide (Fig. 5). In contrast, the
octamer P8I was not detected. These experiments endorse the
antigenicity and complex formation assays (Fig. 4 and Table I)
as a valid approach to the identification of naturally processed
peptides. In conclusion, this result definitively confirmed that
the G9I nonamer was endogenously processed from HIV ENV
glycoprotein and associated to Dd in infected cells.
Some authors observed the strong antigenicity of the G9I
peptide, almost comparable to that of the R10I decamer (18,
19). However, another group reported later that this mono-
charged nonapeptide was essentially not antigenic (20), and
this latter report was widely accepted as an indication that the
optimal synthetic peptide was, by far, R10I. This was sup-
ported by the excellent fit of the R10I peptide into the Dd
molecule, as revealed by crystallographic studies (38, 39). On
this light, it was unexpected to find this monocharged G9I
species as a result of endogenous processing. The discordance
in the reports (18, 19) (and this report), versus (20) might be
due to differences in the experimental settings. Our findings
now of the G9I synthetic peptide as strongly antigenic and
capable of inducing MHC/peptide complexes and, most impor-
tantly, our identification by mass spectrometry of G9I as one of
the endogenously processed peptides, finally settle this contro-
versy. In addition, these results underlie the importance of
identifying the naturally processed peptides because results
with synthetic peptides may bias further research.
The Second Set of Bi-charged, Dd-associated Peptidic Spe-
cies—The second antigenic peak of the cation-exchange column
(fractions 35–37, Fig. 3) coelutes with those bi-charged species
that have a positive charge directly at the N-terminal residue
or in position 2. Close proximity of the positive charges in the
peptide promotes repeated binding of the peptide molecules to
the anionic residues in the HPLC column resin, additionally
retarding their elution. Most bi-charged synthetic peptides did
not coelute with this natural peptide peak, but at earlier frac-
tions, around fraction 28, as their positively charged residues
FIG. 4. Exogenous presentation and MHC stability assay of
mono-charged synthetic ENV peptides. Panel A, Recognition by
CTL of titration curves of G7I (f), P8I (Œ), and G9I (●) synthetic ENV
peptides. Panel B, stability of cell surface MHC/peptide complexes
measured by flow cytometry. Peptides: same code as in panel A. Results
are the mean of at least three experiments.
TABLE I
Functional properties of synthetic peptides and overview of results











stabilitygName Sequence N-end C-end
R10I RGPGRAFVTI   Yes 2nd 2*d e g
R11G RGPGRAFVTIG  Extended No 2nd 2*  n.d.h
R12K RGPGRAFVTIGK  Extended No None 3* f n.d.
Q11I QRGPGRAFVTI Extended  Yes 2nd 2*  
I12I IQRGPGRAFVTI Extended  Yes None 2  
R13I RIQRGPGRAFVTI Extended  Yes None 3*  n.d.
G9I GPGRAFVTI Deleted  Yes 1st 1  
G10G GPGRAFVTIG Deleted Extended No 1st 1  n.d.
G11K GPGRAFVTIGK Deleted Extended No None 2 f n.d.
G12I GPGRAFVTIGKI Deleted Extended Yes None 2  n.d.
Q12G QRGPGRAFVTIG Extended Extended No 2nd 2*  n.d.
I14K IQRGPGRAFVTIGK Extended Extended No 2nd 3 f n.d.
a Not all tested synthetic peptides are included. Nine peptides that do not add information are not summarized here, notably those with
longer extensions.
b The terms deleted or extended are in reference to the termini of the boldface R10I peptide (first peptide in the table).
c Two antigenic peaks were detected in cation-exchange HPLC (IE-HPLC) runs of infected cell extracts, as shown in Fig. 3, and are referred here
to as the 1st and 2nd peak. When synthetic peptides were individually analyzed by cation-exchange HPLC, its elution in any of the fractions of
either peak is scored here as coelution. Peptides with 1 positive charge coelute with the 1st peak. Peptides with 2* (see footnote d, positive charges
coelute with the 2nd peak (Fig. 6).
d The numbers refer to the number of positively charged residues (Arg, Lys, or His) in the peptide. An asterisk indicates that the positive residue
is in position 1 or 2 of the peptide, since this property markedly retards elution in cation-exchange HPLC.
e Peptides were serially diluted in 10-fold steps, and sequentially incubated with targets and CTL. Each additional  sign indicates a 10-fold
higher antigenicity of the respective peptide.
f A peptidyl-carboxydipeptidase activity present in fetal calf serum removes the -GK C-terminal extension (26), and artificially improves
antigenicity of several peptides tested in this series.
g MHC/peptide stability assays were performed as indicated in “Experimental Procedures.” The  signs have a qualitative meaning: :
abundant and stable complexes; : abundant but slightly less stable complexes. See Fig. 7B for the actual comparative data.
h n.d., not done.
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are located further away from position 1. As for monocharged
peptides, similar analyses of bi-charged synthetic peptide coe-
lution in both ion exchange-HPLC and RP-HPLC systems were
performed (Fig. 6, A and B, respectively). From 11 possible
bi-charged ENV peptides containing the antigenic core, one
was excluded because of its deduced irrelevant elution profile,
and 10 were tested. From these, only four had a positive charge
at position 1 or 2, and only these four peptides coeluted with
the natural antigenic activity from the ion exchange column
(Fig. 6A). Only two of these, R10I and Q11I, which differ
between them by one N-terminal residue, are compatible with
the RP-HPLC antigenic peak (Fig. 6B). Unfortunately, at-
tempts to discriminate between R10I and Q11I peptides by
analyzing the antigenic fractions by mass spectrometry were
compromised by the lack of sensitivity. Indeed, fragmentation
of synthetic R10I and Q11I is at least 10-fold less efficient than
that of synthetic G9I (data not shown). The presence of an
additional R in these two peptides as compared with G9I may
have contributed to further decreased efficiency of detection of
fragmented ions, already close to detection limit for the natural
G9I peptide. However, the detection of a signal corresponding
to the fragmentation ion of the C-terminal tetrapeptide FVTI of
the R10I peptide was compatible with the presence of this
decameric molecular species in fraction 37 of the cation-ex-
change run.
In addition to some bi-charged peptides (Table I, 2* charges),
FIG. 5. Identification by mass spectrometry of G9I in infected cell extracts. MS/MS fragmentation spectrum obtained after quadropole
ion trap mass spectrometry of fraction 21 of the cation-exchange run of extracts of L/Dd cells infected with rVV-ENV and shown in Fig. 3. The
vertical axis represents the relative abundance of each fragmentation ion with respect to the parental ion corresponding to the G9I peptide, which
has a mass/charge ratio of 458.4. Ions generated in the fragmentation are detailed for different mass/charge intervals in the three panels, while
the sequence deduced from the indicated fragments is shown in the central box.
FIG. 6. Elution of bi-charged ENV
synthetic peptides in HPLC gradi-
ents. Different bi-charged ENV synthetic
peptides, as indicated, were analyzed in-
dependently by cation-exchange HPLC
(IE-HPLC, left panel) or RP-HPLC (right).
Arrows indicate fraction of elution of the
A280 peak. For reference, CTL results (x)
with natural, extracted peptides from
1.13  108 (left) or 0.72  108 (right) cell
equivalents of L/Dd cells infected with
rVV-ENV at a m.o.i. of 10 are shown.
FIG. 7. Exogenous presentation and MHC stability assay of
bi-charged synthetic ENV peptides. Panel A, recognition by CTL of
titration curves of bi-charged R10I (Œ), and Q11I (f) synthetic ENV
peptides compared with the mono-charged G9I (●) peptide. Panel B,
stability of cell surface MHC/peptide complexes assessed by flow cytom-
etry. Peptides: same code as in panel A.
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some tri-charged peptides (Table I, 3 charges) also co-eluted
with the second antigenic peak of the cation-exchange column.
The shortest example of such peptides, all of which are longer
than 13 residues and have bi-terminal extensions of the 10mer
core, is I14K (Table I). However, failure to co-elute with the
antigenic peak in RP-HPLC excluded them as candidate natu-
ral peptides.
Further characterization of the bi-charged candidate synthetic
peptides (Fig. 7A) shows that ENV-specific CTL similarly and
efficiently recognize both R10I and Q11I. Previous reports of lack
of antigenicity of the Q11I peptide were ascribed to cyclization of
the N-terminal Gln (20), which was excluded in our purified
peptide by mass spectrometry. Potential contamination with
strongly antigenic G9I was discarded, as purification of our Q11I
peptide was performed by cation-exchange chromatography.
Contamination of Q11I with a more antigenic species, specifically
with R10I, was similarly excluded by mass spectrometry (data
not shown). Notably, Fig. 7A also shows that the mono-charged
G9I peptide identified above presents identical titration curve as
both bi-charged peptides. This was true for CTL lines established
by in vitro restimulation with either G9I or R10I peptides (data
not shown). Next, MHC/peptide complex stability analyses were
conducted with the synthetic peptides corresponding to the iden-
tified mono-charged natural species G9I and with the two candi-
date bi-charged species R10I and Q11I. Fig. 7B shows that the
stability of the Dd/G9I complexes was lower, which might be
explained by its loss of an anchor position (see “Discussion”). But,
remarkably, the results shown in Fig. 7B indicated similar rates
of complex formation in all three cases (time point 0). Provided
similar intracellular pools of each peptide are available, this is
compatible with either of the three peptides having the same
chance of being selected for binding to MHC class I from a pool of
different naturally processed peptides available intracellularly.
To study in depth the in vivo relevance of these nested
natural Dd ligands, both primary CD8 responses at 7 days
postinfection and memory CD8 responses at 33 days postin-
fection were quantitated by ICS. This method provides a more
direct measure of CD8 T lymphocyte priming than does meas-
uring lytic activity of secondary in vitro CTL cultures. As
shown in Fig. 8, all three peptides induced secretion of IFN by
activated CD8 cells. Peptide G9I-recognizing CD8 T lympho-
cytes were slightly less abundant that those reacting to the
R10I or Q11I peptides, both in the primary and in the memory
situation, fully in agreement with the slightly lower stability of
Dd/G9I complexes as compared with Dd/R10I or Dd/Q11I
(Fig. 7B).
Recognition by CTL of serial dilutions of the two antigenic
peaks from the ion-exchange chromatography revealed that
both activities were present in approximately similar amounts
in the original infected cells (Fig. 3). As all three candidate
peptides bound equally well to Dd and were also recognized
similarly by CTL, it was concluded that the pool of Dd-bound
natural peptides in ENV-expressing infected cells consisted of
similar amounts of the G9I peptide and of either the R10I or
the Q11I peptide, or both.
The Shorter Peptidic Species Is Not Generated from the Lon-
ger Ones by the Extraction Procedure—As the two bi-charged
candidate natural peptides Q11I and R10I contain and are
longer than the monocharged G9I peptide, the latter one could
potentially be artificially generated from the former two pep-
tides by an aminopeptidase activity or by a chemical reaction
during the biochemical isolation of naturally processed pep-
tides. To exclude this possibility, similar extraction experi-
ments as those performed with rVV-ENV-infected cells were
carried out with R10I and Q11I-pulsed Dd-positive target cells.
Following RP- and cation-exchange HPLC, collected fractions
from this control experiment were tested with CTL and ana-
lyzed by mass spectrometry. No production (less than 6%, as
calculated from the detection limit of the CTL assay) of G9I
peptide, or of any mono-charged antigenic species, was found in
these assays (Fig. 9A). No evidence of generation of R10I from
the longer Q11I, or of cyclization of the N-terminal Q during
extract preparation was observed either by mass spectrometry
(Fig. 9B). These data thus confirm the endogenous generation
of G9I in rVV-ENV-infected cells. Additionally, it was con-
firmed that the R10I and Q11I peptides were not modified by
the biochemical extraction, reinforcing their identification as
candidate natural peptides in infected cells.
In conclusion, these results indicate that the endogenous
processing of the envelope glycoprotein of the HIV-1 strain IIIB
generates, at least, two different molecular species that are
bound to the presenting molecule in the infected cell. Of these,
at least one of them is different to the decamer peptide previ-
ously assumed (20) as the optimal synthetic peptide in the ENV
glycoprotein-specific CTL immune response, and unexpectedly
lacks the terminal NH3
 group anchor.
Effect of N- and C-terminal Extensions on MHC/Peptide/
CTL Interaction—Resolution of the crystal structure of the
R10I peptide bound to Dd (38, 39), as well as analysis of the pool
of natural endogenous peptides presented by Dd (40), jointly
provide a basis for predicting the binding conformation of the
shorter as well as maybe longer peptides found in this study. To
complement this set of information, antigenicity for CTL, as
well as Dd/peptide complex stability, was assayed for an ex-
tended series of synthetic peptides. As shown in Table I, single
or double C-terminal extensions of the R10I core had a moder-
ate negative effect on antigenicity, while single or double ex-
tensions at the N terminus were still as efficiently recognized
by CTL as the optimal peptide. Further N-terminal extensions
only very gradually led to decreased antigenicity. Specifically, a
FIG. 8. Ex vivo populations of CD8
T lymphocytes responsive to syn-
thetic ENV peptides. Splenocytes from
rVV-ENV-infected mice were tested in an
ICS assay either after primary infection
(7 days postinfection, left panel) or in the
memory phase (33 days postinfection,
right panel) with ENV synthetic peptides.
Percentages of total CD8 lymphocytes
that stained for IFN- after stimulation
with the indicated peptides are shown.
Data are the mean of 5 mice from three
independent experiments for the 7-day
(left panel) and one representative exper-
iment for the memory (right panel).
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three-residue N-terminal extension in R13I was still as anti-
genic as a single-residue carboxyl extension in R11G. These
results are essentially compatible with partial data presented
by other groups with some of these peptides (18, 20), before
endogenous natural peptides were identified in our present
report.
Analysis of a second set of peptides in Table I reveals that
removal of the N-terminal amino acid R, as in peptide G9I, did
not have a significantly deleterious effect. This is coherent with
the lack of effect of N-terminal extensions observed above.
However, in this G9I context, combination with C-terminal
extensions had a very drastic effect. Similarly, a third set of
peptides with combined N- and C-terminal extensions were
barely antigenic, starting already with Q12G. This is in full
agreement with the described cumulative effect of combined N-
and C-terminal alterations on peptide antigenicity (41, 42),
while single alterations were fully tolerated (41).
Collectively, this set of data reveals a remarkable tolerance
of Dd and CTL for N-terminal alterations of the 10-mer epitope,
unprecedented for other MHC class I complexes, a more dele-
terious effect of C-terminal elongations, while the alteration of
both termini essentially abrogates functionality.
FIG. 9. Control extracts of unin-
fected Dd-positive cells with syn-
thetic peptides. Peptides were extracted
from uninfected P13.1 cells to which syn-
thetic Q11I and R10I had been added
prior to extraction, and separated by RP-
HPLC. Antigenic fractions were selected,
further separated by cation-exchange
chromatography (IE-HPLC) and tested
again with CTL (panel A). The results
obtained with 1.2 (●), 0.15 (Œ), and 0.04
(f) initial nmol of either synthetic peptide
in the control extracts are plotted. Panel
B shows the MALDI-TOF mass spectrom-
etry spectrum of antigenic fraction 37 of
the cation-exchange chromatography. A
mass/charge ratio of 1073.63 corresponds
to the R10I peptide, and that of 1201.74 to
Q11I.
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The results reported here demonstrate that the endogenous
processing of the HIV-1 envelope glycoprotein generates, at
least, two different peptidic species that are bound to and
presented by the H-2Dd molecule in infected cells. They are the
nonamer G9I (319GPGRAFVTI327) and either its N-terminal
extension R10I (318RGPGRAFVTI327) or its N-terminal double
extension Q11I (317QRGPGRAFVTI327). All three peptides in-
duce high numbers of MHC/peptide complexes and are effi-
ciently presented to CTL. To our knowledge, this is the first
report of naturally processed peptides derived from HIV ENV
protein, and the first time that a naturally processed MHC-
bound ligand derived from an HIV protein is unequivocally
identified by mass spectrometry. Furthermore, it is the first
description of an N-terminally-extended nested set of equally
abundant and antigenic natural peptides bound to MHC class
I molecules. The unexpected existence of two to three peptidic
variants recognized by CTL with the same antigenicity indi-
cates the complexity of antigen presentation, which is some-
times minimized in epitope-detection assays with synthetic
peptides.
Previous analysis of synthetic peptides described the R10I
peptide as the optimal ENV peptide for Dd (17–21). While
intracellular selection by MHC class I molecules of naturally
processed peptides frequently coincides with the optimal syn-
thetic peptide, this is by no means the rule. There are several
studies that show that the natural peptide derived from viral
proteins (43, 44) does not match that suggested from synthetic
peptide recognition analysis (45, 46). Other reports reveal a
more complex nested set of natural viral peptides that are
presented by the same MHC class I molecule, and that com-
prise very weakly antigenic C-terminal extensions of the anti-
genically optimal core identified with synthetic peptides (15,
47). Our study also reveals that the natural situation is more
complex than that deduced from studies with synthetic pep-
tides, and presents the first example of N-terminal variations
of a natural viral peptide. As a crucial novelty compared with
previous reports (15, 47), all HIV ENV natural peptide/MHC
complexes identified by us are expected to contribute signifi-
cantly to the physiological CTL response in the infected mouse,
as all of them are equally abundant and antigenic, and similar
numbers of specific CTL are found for each peptide in vivo. All
these results show the importance of the analysis of natural
peptides that result from the endogenous processing of viral
proteins, as this is fundamental for a detailed understanding of
MHC class I-restricted immunity. Extension of these results in
the mouse model to studies with patient CTL will contribute to
vaccine design.
A striking exception was found with the N-terminally ex-
tended I12I peptide, which was as antigenic and as efficient in
forming stable complexes with Dd as the other three MHC
peptidic ligands, Q11I, R10I, and G9I (Table I). Simple exper-
iments with synthetic peptides would have qualified it as a
very probable candidate natural peptide. And yet, because its
elution profile in the cation-exchange HPLC column corre-
sponded to fraction 30, devoid of antigenicity in the infected cell
extracts, it was concluded that it was not present among the
pool of naturally processed peptides. Because the evidence in-
dicates that intracellular Dd would bind this peptide if given
the chance, this implies that this I12I peptide may not be
produced by the proteasome. Alternatively, it might be rapidly
converted into shorter variants before it binds, or after binding
(48) to Dd. Thus, the I12I peptide represents a paradigm where
analysis of natural endogenous peptides is critically required to
unequivocally establish the physiological relevance of a very
antigenic synthetic peptide.
Concerning transport by TAP, peptides I12I and Q11I, as
well as potential longer precursors, would not have any theo-
retical limitations. However, transport of the decamer R10I
and of the nonamer G9I would be disfavored by murine TAP,
because they have a P at position 3 and 2, respectively (49–51).
Thus, G9I, and R10I if confirmed as a natural peptide in
murine cells, would be generated from a longer precursor that
is efficiently transported into the endoplasmic reticulum.
Among other possibilities, this precursor might well be the
Q11I peptide itself.
Once in the secretory pathway, either endoproteases or amin-
opeptidases should produce the proximal N-terminal cleavages to
yield the final peptides. Specifically, a crucial protease should be
an uncharacterized metallopeptidase that operates in a sequen-
tial pathway with the proteasomes to process ENV (28). In the
endoplasmic reticulum, a metallo-aminopeptidase has been de-
scribed that leads to the accumulation of peptides with P at
position 2 (52). This aminopeptidase could be responsible for the
production of G9I, and a potential accumulation of this peptide
would result in its over-representation in the pool of natural
peptides, despite the lower stability of the Dd/G9I complexes.
This aminopeptidase, or others (53, 54, 59), could also sequen-
tially have generated the undecamer and the decamer, although
it is also possible that these peptides are generated individually
from longer precursors by endo- or tripeptidyl- or dipeptidyl-
aminopeptidases (53).
Whereas most MHC class I molecules require two major
anchor residues in the antigenic peptide, the Dd allele has an
unusual binding motif with three major anchors (Gly at posi-
tion 2, Pro at 3, and Leu, Ile, or Phe at the C-terminal position)
and a positively charged residue at position 5 (40). This fourth
anchor residue is due to the presence of two Trp residues (at
positions 97 and 114 of Dd), which form a wall within the
binding groove that forces the peptide to arch over the wall to
anchor the C-terminal residue (39), and permits that peptide
positions 6, 7, and 8 protrude above the protein surface and
have high solvent accessibility. As a consequence, the side
chains of these residues are more accessible for recognition by
specific CTL. Crystallographic studies (38, 39) show that the
R10I peptide binds to the presenting molecule Dd with the
lateral chain of the C-terminal residue anchored in the F
pocket. The NH3
 group of the N-terminal Arg binds to the A
pocket, while its lateral chain points out of the groove. Posi-
tions 2G, 3P, 5R, and 10I are deeply buried in the groove, and
confer a more constrained conformation to R10I than that of
peptides bound to other MHC alleles. Collectively, the data
suggest that the nonamer G9I binds to Dd in a very similar
conformation as R10I does, with each side chain occupying a
similar position as those of R10I in the elucidated Dd/R10I
complex. The only and important difference between both Dd-
bound peptides would be the lack of interaction of the terminal
NH3
 group of G9I with the A pocket residues. This model (Fig.
10) for G9I binding to Dd accounts for the identical antigenic
recognition of both G9I and R10I peptides by CTL despite the
weaker stability of the Dd/G9I complexes. Furthermore, the
lack of strict requirement for the NH3
 group interaction is
supported by the striking lack of effect of its loss in peptides
elongated several amino acids on the N terminus (Table I).
As the R10I peptide is highly constrained by four anchor
motifs and position 1 protrudes above the surface of the Dd
molecule, the simplest possibility is that the additional amino-
extended residue 1Q of the Q11I peptide reaches out of the
peptide cleft (Fig. 10) without altering the peptide surface
exposed to TCR recognition. This is compatible with peptides
G9I, R10I, and Q11I showing similar complex formation rates
and identical recognition curves by specific CTL. In addition,
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this conclusion is further reinforced by the observation that the
12-mer N-terminal elongated peptide I12I was also as effi-
ciently recognized by the same specific CTL, and as efficient in
complex formation with Dd, and by the fact that peptides with
longer N-terminal extensions were still remarkably antigenic.
In contrast, C-terminal extensions are disfavored, maybe be-
cause position 10I is deeply buried into the hydrophobic F
pocket and allows for little flexibility.
The occurrence of G9I or Q11I as natural peptides would not
have been predicted, however, from analysis of the cellular
peptides eluted from Dd molecules (40). Only 9 or 10 amino
acid-long peptides with both NH3
 and carboxyl anchors were
identified, that differed only in the degree of central bulging.
This is the most frequent structural adaptation for accommo-
dating longer peptides by MHC class I molecules. Binding of
G9I without an NH3
 group anchor, as indicated by our evi-
dence, is supported by the existence of peptides lacking the
N-terminal binding residue that nevertheless bind endog-
enously to other MHC class I molecules (55), which indicates
that canonical MHC-peptide interactions in the A pocket are
not always necessary for endogenous peptide presentation.
Regarding Q11I, if confirmed, it would represent just the
second report of an N-terminal extended natural peptide, and
the first case where the MHC/peptide complex is abundant and
antigenic enough to contribute to the physiological CTL re-
sponse. Indeed, in the previously described example, the
amount and the antigenicity of the complexes with the amino-
extended precursor were both 100-fold lower than those of the
final core peptide (48). In contrast, several instances of longer
than canonical endogenous peptides that very likely protrude
on the C terminus have been reported (15, 47, 56–58), although
comparable antigenicity to the core epitope has not been dem-
onstrated for any of them. A likely explanation for this bias
toward carboxyl extensions is the existence of aminopepti-
dases, but not of carboxypeptidases, in the proximal part of the
secretory route, where most MHC/peptide complexes are
formed. These aminopeptidases might trim (48) a fraction of
the Q11I/Dd complexes and reduce their relative presence at
the plasma membrane, increasing the numbers of surface R10I
and/or G9I complexes.
The diversity of MHC/peptide complexes can be an advan-
tage for the immune system. First, a wider variety of complexes
can activate a wider repertoire of T-cell clonotypes, generating
a more solid CTL response. Even if the residues shared by all
natural peptides bind similarly to Dd, additional extending
residues can individually contribute to recognition by the TCR
(42). Second, one advantage of this richness of MHC/peptide
complexes is that none of them is strictly necessary to generate
a response. For example, although Q11I is a very good candi-
date natural precursor or ligand, it is not a necessary molecule,
as the eC-10env full-length chimeric protein that lacks the
N-terminal Gln can nevertheless be processed for presentation
by Dd (28). Thus, the existence of multiple MHC/peptide com-
plexes can deaden the negative effects of antigen variability
and reduce the likelihood of appearance of CTL escape variants
(1, 10, 11). It is a paradox that a hypervariable region of HIV
ENV protein, as the V3 loop, is nevertheless such a good source
of epitopes from many different HIV strains and in a high
number of patients. Our results contribute to an explanation.
Apparently, several different peptides can be processed from
this area. From this pool, a single MHC class I molecule, Dd,
already can sample two or three different peptides to complex
with. Even after natural variation of the epitope environment
in the viral protein, that may preclude the generation of indi-
vidual species, some of the peptides would still be processed,
still allowing for antigen presentation and thus for the gener-
ation of an efficient CTL immune response. A third advantage
of generating a pool of processed peptides is that it can allow
presentation of related but distinct peptides by a wider number
of different MHC class I alleles, as indeed is the case for this
FIG. 10. A model for binding of pep-
tides G9I and Q11I to Dd. The model for
the G9I/Dd and the Q11I/Dd complexes is
based on the crystal structure of the
R10I/Dd complex (38, 39) and the results
reported in this article. Side chains of
peptide residues are represented by filled
rectangles to indicate interaction with Dd
or exposure to the T-cell receptor, TCR.
Void rectangles indicate lower or no inter-
action. The main chain of the most N-
terminal Gly is similarly represented
with a filled small square where it inter-
acts with Dd.
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epitopic area (22), providing a more extended immunity to the
population.
Identification of the natural peptides presented by further
murine and human MHC class I molecules is needed, not only
to confirm this hypothesis, but also to learn more about the
general rules of antigen processing, and specifically in this
antigenic area. In addition, the knowledge obtained from these
and future studies on endogenous peptides can help prevent
biases in vaccine research. Clinical trials have started with
recombinant constructs containing multiple minimal epitopes
linked in a string. With the limited knowledge uncovered by
our experiments in the murine model, we can already propose
that a larger area, including Q11I and possibly extended to the
unknown sequences that allow the generation of multiple pro-
cessed products, should be included in any vaccine formulation
aiming at inducing a solid CTL immunity to the HIV envelope
glycoprotein in several HLA backgrounds.
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P. Martı́nez is gratefully acknowledged.
REFERENCES
1. McMichael, A. J., and Phillips, R. E. (1997) Annu. Rev. Immunol. 15, 271–296
2. Hogan, C. M., and Hammer, S. M. (2001) Ann. Intern. Med. 134, 761–776
3. Koup, R. A., Safrit, J. T., Cao, Y., Andrews, C. A., McLeod, G., Borkowsky, W.,
Farthing, C., and Ho, D. D. (1994) J. Virol. 68, 4650–4655
4. Borrow, P., Lewicki, H., Hahn, B. H., Shaw, G. M., and Oldstone, M. B. A.
(1994) J. Virol. 68, 6103–6110
5. Haynes, B. F., Pantaleo, G., and Fauci, A. S. (1996) Science 271, 324–328
6. Cao, Y., Qin, L., Zhang, L., Safrit, J., and Ho, D. D. (1995) N. Engl. J. Med. 332,
201–208
7. Schmitz, J. E., Kuroda, M. J., Santra, S., Sasseville, V. G., Simon, M. A., Lifton,
M. A., Racz, P., Tenner-Racz, K., Dalesandro, M., Scallon, B. J., Ghrayeb, J.,
Forman, M. A., Montefiori, D. C., Rieber, E. P., Letvin, N. L., and Reimann,
K. A. (1999) Science 283, 857–860
8. Carrington, M., Nelson, G. W., Martin, M. P., Kissner, T., Vlahov, D., Goedert,
J. J., Kaslow, R., Buchbinder, S., Hoots, K., and O’Brien, S. J. (1999) Science
283, 1748–1752
9. Kaslow, R. A., Carrington, M., Apple, R., Park, L., Munoz, A., Saah, A. J.,
Goedert, J. J., Winkler, C., Obrien, S. J., Rinaldo, C., Detels, R., Blattner,
W., Phair, J., Erlich, H., and Mann, D. L. (1996) Nat. Med. 2, 405–411
10. Goulder, P. J. R., Phillips, R. E., Colbert, R. A., McAdam, S., Ogg, G., Nowak,
M. A., Giangrande, P., Luzzi, G., Morgan, B., Edwards, A., McMichael, A. J.,
and Rowland-Jones, S. (1997) Nat. Med. 3, 212–217
11. Borrow, P., Lewicki, H., Wei, X. P., Horwitz, M. S., Peffer, N., Meyers, H.,
Nelson, J. A., Gairin, J. E., Hahn, B. H., Oldstone, M. B. A., and Shaw, G. M.
(1997) Nat. Med. 3, 205–211
12. Yusim, K., Kesmir, C., Gaschen, B., Addo, M. M., Altfeld, M., Brunak, S.,
Chigaev, A., Detours, V., and Korber, B. T. (2002) J. Virol. 76, 8757–8768
13. Tsomides, T. J., Aldovini, A., Johnson, R. P., Walker, B. D., Young, R. A., and
Eisen, H. N. (1994) J. Exp. Med. 180, 1283–1293
14. Tomiyama, H., Yamada, N., Komatsu, H., Hirayama, K., and Takiguchi, M.
(2000) Eur. J. Immunol. 30, 2521–2530
15. Lucchiari-Hartz, M., Van Endert, P. M., Lauvau, G., Maier, R., Meyerhans, A.,
Mann, D., Eichmann, K., and Niedermann, G. (2000) J. Exp. Med. 191,
239–252
16. Takahashi, H., Cohen, J., Hosmalin, A., Cease, K. B., Houghten, R., Cornette,
J. L., DeLisi, C., Moss, B., Germain, R. N., and Berzofsky, J. A. (1988) Proc.
Natl. Acad. Sci. U. S. A. 85, 3105–3109
17. Shirai, M., Pendleton, C. D., and Berzofsky, J. A. (1992) J. Immunol. 148,
1657–1667
18. Bergmann, C., Stohlmann, S. A., and McMillan, M. (1993) Eur. J. Immunol.
23, 2777–2781
19. Bergmann, C., Tong, L., Cua, R. V., Sensintaffar, J. L., and Stohlman, S. A.
(1994) J. Immunol. 152, 5603–5612
20. Takeshita, T., Takahashi, H., Kozlowski, S., Ahlers, J. D., Pendleton, C. D.,
Moore, R. L., Nakagawa, Y., Yokomuro, K., Fox, B. S., Margulies, D. H., and
Berzofsky, J. A. (1995) J. Immunol. 154, 1973–1986
21. Shirai, M., Kurokohchi, K., Pendleton, C. D., Arichi, T., Boyd, L. F., Takahashi,
H., Margulies, D. H., and Berzofsky, J. A. (1996) J. Immunol. 157,
4399–4411
22. Korber, B. T. M., Brander, C., Haynes, B. F., Koup, R., Kuiken, C., Moore, J. P.,
Walker, B. D., and Watkins, D. (2001) Theoretical Biology and Biophysics
Group, Los Alamos National Laboratory, Los Alamos, NM
23. Carbone, F. R., and Bevan, M. J. (1990) J. Exp. Med. 171, 377–387
24. Abastado, J. P., Jaulin, C., Schutze, M. P., Langlade-Demoyen, P., Plata, F.,
Ozato, K., and Kourilsky, P. (1987) J. Exp. Med. 166, 327–340
25. Salter, R. D., and Cresswell, P. (1986) EMBO J. 5, 943–949
26. Kozlowski, S., Corr, M., Takeshita, T., Boyd, L. F., Pendleton, C. D., Germain,
R. N., Berzofsky, J. A., and Margulies, D. H. (1992) J. Exp. Med. 175,
1417–1422
27. Chakrabarti, S., Robert-Guroff, M., Wong-Staal, F., Gallo, R. C., and Moss, B.
(1986) Nature 320, 535–537
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53. Del Val, M., and López, D. (2002) Mol. Immunol. 39, 235–247
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